Adma Biologics(NASDAQ) ADMA

ADMA helps people with weak immune systems fight off dangerous infections. It makes special medicines from human blood plasma to protect these patients. These treatments give patients the antibodies they need to stay healthy.

Treatments for the Immune Compromised

• ASCENIV: Specialty immune globulin used to treat adults and adolescents with inherited immune system defects.
• BIVIGAM: Standard immune globulin used to treat patients aged two and older with primary immunodeficiency.
• Nabi-HB: Targeted antibody treatment for people who have been exposed to the Hepatitis B virus.
• Plasma Collection: Facilities that collect the raw human blood plasma needed to create the company's specialty medicines.

Strategic Moves and Supply Deals

• Acquired real estate in Boca Raton, FL in July 2025 for $12.6 million to expand storage.
• Agreed to sell three plasma collection centers in December 2025 for $12 million.
• Extended a long-term supply agreement with Grifols through 2039 to secure raw materials.
• Partnered with KEDPlasma in August 2024 to provide an additional source of human plasma.

What Makes ADMA Different

ADMA manages the entire process from collecting human plasma to manufacturing finished medicines in its Florida facility. The company uses an artificial intelligence program called ADMAlytics to predict production outcomes and increase efficiency across its supply chain.

By the Numbers

• Revenue was $139.2 million in Q4 2025, up 18.4% from Q4 2024.
• Gross profit reached $88.8 million in Q4 2025, up 40.2% from the previous year.
• Operating income hit $62.8 million in Q4 2025, up 63.7% year-over-year.
• Market capitalization grew to $4.3 billion in Q4 2025, up 7% from Q4 2024.

Bottom Line

ADMA has evolved into a vertically integrated company by controlling its own manufacturing and supply chain. Its focus on specialized blood-derived treatments and efficiency technology supports its market position.